Excellent all round results as forecasted by management. Same goes for the 2024 forecast.
My question is still about VYVGART impact on CIDP patients. I understand this will not have impact for few more years of CSL sales. One day it will. Enthusiasm for Argnex by investors after the update of VYVGART on CIDP says something.
As CEO mentioned in Q&A that IG still remains the preferred product. But if VYVGART has the same efficacy and only 1 hour to get treated compared to 8 hours with intravenous IG, which one will you take in few years time.?
CIDP is big portions of CSL revenue. Therefore I would like to see at least new product like csl112 which can compensate possible hole in revenue in CIDP.
Still on long run it is great company as it will bring other products to the market too. Any other views?
Excellent all round results as forecasted by management. Same...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.83 |
Change
-2.170(0.73%) |
Mkt cap ! $142.3B | |||
| Open | High | Low | Value | Volume |
| $294.28 | $295.68 | $293.35 | $45.01M | 153.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 41 | $293.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.83 | 25 | 2 |
View Market Depth
| Last trade - 12.42pm 18/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |